Products
Pre-made Epcoritamab benchmark antibody ( Bispecific mAb, anti-CD3E;MS4A1/CD20 therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-189
Pre-Made Epcoritamab biosimilar, Bispecific mAb, Anti-CD3E;MS4A1/CD20 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Envafolimab is a novel, single-domain PD-L1 antibody that is administered by subcutaneous injection without the need for an adjuvant.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-189-1mg | 1mg | Inquiry | ||
| GMP-Bios-ab-189-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-189-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-189-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Epcoritamab biosimilar, Bispecific mAb, Anti-CD3E;MS4A1/CD20 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody |
| INN Name | Epcoritamab |
| Target | CD3E;CD20 |
| Format | Bispecific mAb |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;3giz:HL/6y92:BA:HL |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Genmab |
| Conditions Approved | na |
| Conditions Active | Haematological malignancies;Diffuse large B-cell lymphoma;Chronic lymphocytic leukaemia;Follicular lymphoma;Non-Hodgkin's lymphoma |
| Conditions Discontinued | na |
| Development Tech | na |
<